2109 is designed as a long acting hormone replacement therapy targeting chronic hypoparathyroidism, or HP. It uses the company’s proprietary PEP platform to produce “a continuous, infusion-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback